A neurologist's personal battle against Alzheimer's disease
The results of the phase 3 clinical trial of the anti-amyloid monoclonal antibody donanemab were released simultaneously today at the Alzheimer’s Association Clinical Conference (AAIC) in Amsterdam and in a paper published in JAMA....
Two important things happened this week. On the Fourth of July, my granddaughter Emily got her first ride in a canoe. She was thrilled. The other important thing that happened this week was the FDA...
Cobe Haskell and Bill Ward are two of my oldest friends. I have known them since fourth grade. In 1964 or possibly 1963, Cobe and I started putting together a rock band. In the beginning, our...
Last March on this blogsite, I described evidence that chronic laxative use can increase the risk of getting dementia. The cause of this increased risk was thought to involve disruption of the gut microbiome, the...
After years of failed trials, two and possibly three anti-amyloid monoclonal antibodies have shown efficacy at removing beta-amyloid from the brain of subjects with mild Alzheimer’s disease. Two of them, lecanemab and donanemab, have...
There are now two anti-amyloid monoclonal antibodies that appear to be effective in slowing the progression of cognitive impairment in people with mild Alzheimer’s disease. The benefit may be small, 27% for lecanemab and...
Yesterday Eli Lilly issued a press release summarizing positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slows cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab is unique...
Like most people with Alzheimer’s disease, my verbal memory was the first cognitive domain to be affected. Recently it has rapidly been getting worse. On my most recent testing with the Montreal Cognitive Assessment (MoCA),...
Several weeks ago, I signed a contract with the publisher for a collection of essays about Alzheimer’s disease. These are essays I have written over the last several years, and a few days ago I...
Early in my career as a neurologist, probably about 1990, I was asked to consult on a 62-year-old, previously healthy woman who had had a large brain hemorrhage. She had no apparent risk factors...
Recent Comments